Study study type PathologyT1T0Patientssample sizesROB Results

mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone
IMvigor-211 (PDL1>5%), 2018
  NCT02302807
RCTmUC - L2 - PDL1 positiveatezolizumabchemotherapypatients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen patients had received no more than two previous lines of therapy and had progressed during or following one or more platinum-containing regimens for metastatic urothelial carcinoma (or neoadjuvant or adjuvant therapy with progression)116 / 118some concern
inconclusive
  • inconclusive 13 % decrease in deaths (OS) (PE)
IMvigor-211 (PDL1>1%), 2018
  NCT02302807
RCTmUC - L2 - PDL1 positiveatezolizumabchemotherapypatients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen patients had received no more than two previous lines of therapy and had progressed during or following one or more platinum-containing regimens for metastatic urothelial carcinoma (or neoadjuvant or adjuvant therapy with progression316 / 309some concern
suggested
  • inconclusive 13 % decrease in deaths (OS) (PE)